Molecular and cellular pathology of hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue SUPPL.1, 1998, Pages

  Ng, Irene Ol ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatocellular carcinoma; Insulin like growth factor II; p53

Indexed keywords

PROTEIN P21; PROTEIN P53; SOMATOMEDIN B;

APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CONFERENCE PAPER; DISEASE ASSOCIATION; DNA REPAIR; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0031739766     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1998.tb01897.x     Document Type: Article

References (49)

1. Hollstein M, Sidransky D, Volgelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
2. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427-8.
3. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-31.
4. Ozturk M and collaborators. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1992; 338: 1356-9.
5. Scorsone KA, Zhou YZ, Butel JS, Slagle BL. p53 mutation at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res. 1992; 52: 1635-8.
6. Li DZ, Cao YQ, He LP, Wang NJ, Gu JR. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis 1993; 14: 169-73.
7. Shank RC, Wogan GN, Gibson JB. Dietary aflatoxins and human liver cancer. I. Toxigenic moulds in foods and foodstuffs of tropical South-east Asia. Food Cosmet. Toxicol. 1972; 10: 51-60.
8. Shank RC, Wogan GN, Gibson JB, Nondasuta A. Dietary aflatoxins and human liver cancer. II. Aflatoxins in market foods and foodstuffs of Thailand and Hong Kong. Food Cosmet. Toxicol. 1972; 10: 61-9.
9. Chan M. Department of Health Annual Report. Government of Hong Kong, 1998.
10. Ng IOL, Chung LP, Tsang S et al. p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene 1994; 9: 985-90.
11. Ng IOL, Srivastava G, Chung LP, Tsang S, Ng M. Overexpression and point mutations of p53 tumor suppressor gene in hepatocellular carcinomas in Hong Kong Chinese people. Cancer 1994; 74: 30-7.
12. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res. 1992; 52: 6358-64.
13. Sheu JC, Huang GT, Lee PH et al. Mutation of p53 gene in hepatocellular carcinoma in Taiwan. Cancer Res. 1992; 52: 6098-100.
14. Hollstein MC, Wild CP, Bleicher F et al. p53 mutation and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand. Int. J. Cancer 1993; 53: 51-5.
15. Unsal H, Yakicier C, Marcais C et al. Genetic heterogeneity of hepatocellular carcinoma. Proc. Natl Acad. Sci. USA 1994; 91: 822-6.
16. Ng IOL, Lai ECS, Chan ASY, So MKP. p53 gene overexpression in hepatocellular carcinomas in Hong Kong Chinese: A clinicopathological and prognostic correlation. J. Gastroenterol. Hepatol. 1995; 10: 250-5.
17. Hsia CC, Kleiner DE Jr, Axiotis CA et al. Mutations of p53 gene in hepatocellular carcinoma: Roles of hepatitis B virus and aflatoxin contamination in the diet. J. Natl Cancer Inst. 1992; 84: 1638-41.
18. Laurent-Puig P, Flejou JF, Fabre M et al. Overexpression of p53: A rare event in a large series of white patients with hepatocellular carcinoma. Hepatology 1992; 16: 1171-5.
19. Challen C, Lunec J, Warren W, Collier J, Bassendine M. Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology 1992; 16: 1362-6.
20. Choi SW, Hytiroglou P, Geller SA et al. The expression of p53 antigen in primary malignant epithelial tumors of thee liver: An immunohistochemical study. Liver 1993; 13: 172-6.
21. Hsu HC, Tseng HJ, Lai PL, Lee PH, Peng SY. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: Association with tumor growth and invasiveness. Cancer Res. 1993; 53: 4691-4.
22. Tanaka S, Toh Y, Adachi E, Matsumata T, Mori R, Sugimachi K. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res. 1993; 53: 2884-7.
23. 1 arrest and apoptosis. Cancer Res. 1994; 54: 1169-74.
24. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-8.
25. Flores-Rozas H, Kelman Z, Dean FB et al. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase δ holoenzyme. Proc. Natl Acad. Sci. USA 1994; 91: 8655-9.
26. wAF1/CIP1 expression and p53 mutation in hepatocellular carcinomas. Hepatology 1997; 25: 575-9.
27. Furutani M, Arii S, Tanaka H et al. Decreased expression and rare somatic mutation of the CIP1/WAF1 gene in human hepatocellular carcinoma. Cancer Lett. 1997; 111: 191-7.
28. Qin LF, Ng IOL, Fan ST, Ng M. p21/waf1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int. J. Cancer 1998; 79: 424-8.
29. Marchetti A, Doglioni C, Barbareschi M et al. p21 RNA and protein expression in non-small cell lung carcinomas: Evidence of p53-independent expression and association with tumoral differentiation. Oncogene 1996; 12: 1319-24.
30. Wakasugi E, Kobayashi T, Tamaki Y et al. p21 (Waf1/Cip1) and p53 protein expression in breast carcinoma. Am. J. Clin. Pathol. 1997; 107: 684-91.
31. Jung JM, Bruner JM, Ruan S et al. Increased levels of p21 WAF1/Cip1 in human brain tumors. Oncogene 1995; 11: 2021-8.
32. waf-1 in human cutaneous squamous cell carcinoma. Am. J. Pathol. 1996; 149: 1139-46.
33. Lukas J, Groshen S, Asffari B et al. WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary and endometrium. Am. J. Pathol. 1997; 150: 167-75.
34. Fu XX, Su CY, Lee Y et al. Insulin-like growth factor II expression and oval cell proliferation associated with hepatocarcinogenesis in woodchuck hepatitis virus carriers. J. Virol. 1988; 62: 3422-30.
35. Froesch ER, Schmid C, Schwander J, Zapf J. Actions of insulin-like growth factors. Ann. Rev. Physiol. 1985; 47: 443-7.
36. DeChiara TM, Efstratiadis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 1990; 345: 78-80.
37. Dull TJ, Gray A, Hayflick JS, Ullrich A. Insulin-like growth factor II precursor gene organization in relation to insulin gene family. Nature 1984; 310: 777-81.
38. Soares MB, Turken A, Ishii D et al. Rat insulin-like growth factor II gene. A single gene with two promoters expressing a multitranscript family. J. Mol. Biol. 1986; 192: 737-52.
39. De Holthuizen P Pagter, Jansen M, van Schaik FM et al. The human insulin-like growth factor II gene contains two development-specific promoters. FEBS Lett. 1987; 214: 259-64.
40. Sussenbach JS, Steenbergh PH, de Holthuizen P. Pagter Structure and expression of the human insulin-like growth factor genes. Growth Regul. 1992; 2: 1-9.
41. Cariani E, Lasserre C, Seurin D et al. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumours and liver cirrhosis. Cancer Res. 1988; 48: 6844-9.
42. Gray A, Tarn AW, Dull TJ et al. Tissue-specific and developmentally regulated transcription of the insulin-like growth factor II gene. DNA 1987; 6: 283-95.
43. Uneo T, Takahashi K, Matsuguchi T, Ikejiri K, Endo H, Yamamoto M. Reactivation of rat insulin-like growth factor II gene during hepatocarcinogenesis. Carcinogenesis 1988; 9: 1779-83.
44. Su TS, Liu WY, Han SH et al. Transcripts of the insulin-like growth factors I and II in human hepatoma. Cancer Res. 1989; 49: 1773-7.
45. Cariani E, Seurin D, Lasserre C, Franco D, Binoux M, Brechot C. Expression of insulin-like growth factor II (IGF-II) in human primary liver cancer: mRNA and protein analysis. J. Hepatol. 1990; 11: 226-31.
46. Yang D, Rogler CE. Analysis of insulin-like growth factor II (IGF-II) expression in neoplastic nodules and hepatocellular carcinomas of woodchucks utilizing in situ hybridization and immunocytochemistry. Carcinogenesis 1991; 12: 1893-901.
47. Scott J, Cowell J, Robertson ME et al. Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues. Nature 1985; 317: 260-2.
48. Haselbacher GK, Irminger JC, Zapf J, Ziegler WH, Humbel RE. Insulin-like growth factor II in human adrenal pheochromocytomas and Wilms' tumors: Expression at the mRNA and protein level. Proc. Natl Acad. Sci. USA 1987; 84: 1104-6.
49. Ng IOL, Lee J, Srivastava G, Ng M. Role of insulin-like growth factor II in hepatocellular carcinoma: A study of mRNA and pathological features. J. Gastroenterol. Hepatol. 1998; 13: 41-6.